Your shopping cart is currently empty

Neurokinin A TFA (NKA TFA) is a neuropeptide within the neurokinin family, serving as the endogenous ligand and agonist for the NK-2 (Neurokinin 2) receptor. It regulates the nervous system, inflammation, and pain, and is applicable for research into asthma, inflammatory bowel disease, rheumatoid arthritis pain, and psychiatric disorders.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $52 | - | In Stock | |
| 5 mg | $123 | - | In Stock | |
| 10 mg | $213 | - | In Stock | |
| 25 mg | $359 | - | In Stock | |
| 50 mg | $533 | - | In Stock | |
| 100 mg | $759 | - | In Stock | |
| 200 mg | $987 | - | In Stock |
| Description | Neurokinin A TFA (NKA TFA) is a neuropeptide within the neurokinin family, serving as the endogenous ligand and agonist for the NK-2 (Neurokinin 2) receptor. It regulates the nervous system, inflammation, and pain, and is applicable for research into asthma, inflammatory bowel disease, rheumatoid arthritis pain, and psychiatric disorders. |
| In vitro | Neurokinin A TFA is a peptide neurotransmitter belonging to the tachykinin family. All tachykinins share a conserved COOH-terminal structure of Phe-X-Gly-Leu-Met-NH₂, and the most representative members of this family are Substance P and Neurokinin A. Neurokinin A TFA may act as a crucial mediator in human airway and gastrointestinal tissues. It exerts its effects through NK-2 receptors localized on smooth muscle cells and is pharmacologically coupled to GTP-binding proteins. Neurokinin A TFA is associated with both the central and peripheral nervous systems and exhibits a broad tissue distribution pattern. [1] |
| Synonyms | Substance K TFA, NKA TFA, Neuromedin L TFA, Neurokinin α TFA |
| Molecular Weight | 1247.34 |
| Formula | C52H81F3N14O16S |
| Cas No. | 2828433-19-6 |
| Smiles | C(C(O)=O)(F)(F)F.[C@H](CC1=CC=CC=C1)(C(N[C@H](C(NCC(N[C@H](C(N[C@@H](CCSC)C(N)=O)=O)CC(C)C)=O)=O)C(C)C)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC2=CN=CN2)N)=O)CCCCN)=O)[C@@H](C)O)=O)CC(O)=O)=O)CO)=O |
| Sequence | His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2 |
| Sequence Short | HKTDSFVGLM |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (64.14 mM), Sonication is recommended. H2O: 40 mg/mL (32.07 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (2.65 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.